TO: CENTRAL FAX COMPANY:



RECEIVED CENTRAL FAX CENTER

AUG 0-2 2005

Patent Technology Centers

Facsimile Transmission

To:

Name:

CENTRAL FAX

Company:

Fax Number:

571-273-8300

Voice Phone:

From:

Name:

Official Fax Number:

(571) 273-8300

Official After Final Fax Number:

(571) 273-8300

Voice Phone:

37 C.F.R. 1.6 sets forth the types of correspondence that can be communicated to the Patent and Trademark Office via facsimile transmissions. Applicants are advised to use the certificate of facsimile transmission procedures when submitting a reply to a non-final or final Office action by facsimile (37 CFR 1.8(a)).

Fax Notes:

Date and time of transmission: Tuesday, August 02, 2005 4:40:40 PM

Number of pages including this cover sheet: 12

USPTO TO: CENTRAL FAX COMPANY: JUL. 28. 2005

8/2/2005 4:41 PM PAGE

2/012

Fax Server

2:58PM

LVM 312 616 5700

-NO. 5625**---**¹ P. 1•

10 1615044

FACSIMILE TRANSMITTAL COVER SHEET

Date: July 28, 2005

Number of pages (including this transmittal cover sheet): 11

Our Reference: 223505

To:

Commissioner For Patents - Attention: Examiner Taofiq A. Solola

P.O. Box 1450

Art Unit 1626

Alexandria, Virginia 22313-1450

Telephone: (571) 272-0709

Facsimile: (571) 273-0709 or (571) 273-8300 (general #)

From:

Bruce M. Gagala

Leydig, Voit & Mayer, Ltd.

Two Prudential Plaza - Suite 4900 Chicago, Illinois 60601-6780

Telephone: (312) 616-5600 Facsimile: (312) 616-5700

Message: Dear Examiner Solola: Enclosed as we discussed are the amended claims. I believe that we had previously reached agreement with respect to claims 1, 8, 9, 17 and 19-21. We had not previously reached agreement with respect to claim 11, and claims dependent thereon. As to claim 11, we have enclosed website information showing jupac nomenclature for oxamoylation which we would like to discuss with you.

Bruce M. Gagala

THE INFORMATION CONTAINED IN THIS FACSIMILE TRANSMISSION IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY NAMED ABOVE AND THOSE PROPERLY ENTITLED TO ACCESS TO THE INFORMATION AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND/OR EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF THE READER OF THIS TRANSMISSION IS NOT THE INTENDED OR AN AUTHORIZED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY UNAUTHORIZED DISTRIBUTION, DISSEMINATION, OR DUPLICATION OF THIS TRANSMISSION IS PROHIBITED. IF YOU HAVE RECEIVED THIS TRANSMISSION IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE OR FACSIMILE. THANK YOU.